LOXO-305被设计成可逆结合BTK,在C481获得性耐药突变的情况下保持活性,同时避开其他共价和非共价BTK抑制剂开发牵涉的非靶向激酶。 除了先前宣布的3期MCL试验外,Loxo Oncology正在准备对BTK预治疗的CLL/SLL患者启动2项全球随机3期临床试验(BRUIN CLL-321,BRUIN CLL-322),探索LOXO-305作为单药疗法及与其他药物的组合疗...
第18 卷第 11 期 2020 年 11 月 临床药物治疗杂志 Clinical Medication Journal Vol.18,No.11 November,2020 ·未来药物· 新一代非共价酪氨酸激酶抑制剂——LOXO-305 陈永收 1,周加英 2*,周玉琴 2,谢欣蓉 1,曹爽 1 1. 武汉工程大学 化工与制药学院,武汉 430072;2. 扬子江药业集团有限公司,江苏 ...
[2]Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting. Retrieved December 9, 2019, from https://investor.lilly.com/news-releases/news-release-details/lilly-presents-interim-clinical-data-loxo-3...
Pirtobrutinib (LOXO-305) is a highly selective, non-covalent BTKi that inhibits both WT and C481-mutated BTK with equal, low nM potency. To evaluate pirtobrutinib safety and efficacy in pts with CLL/SLL. BRUIN is an ongoing multi-center phase 1/2 trial (NCT03740529). Enrollment was ...
To address these limitations, LOXO-305, a highly selective, non-covalent BTKi that inhibits both wild type (WT) and C481-mutated BTK with equal low nM potency was developed. The aim of the BRUIN trial was to define the safety and early efficacy of LOXO-305 in pts with B-cell ...
(生物谷Bioon.com) 原文出处:Loxo Oncology at Lilly Announces Updated Data from the Phase 1/2 BRUIN Clinical Trial for LOXO-305 in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at the American Society of Hematology Annual Meeting
I think we're going to talk about a very exciting presentation at ASH this year, which was the trial of LOXO-305. I think we're all very excited about this new class of agents, the non-covalently binding BTK [Bruton tyrosine kinase] inhibitors. I'm going to let Anthony, since he wa...
Pirtobrutinib (Synonyms: LOXO-305) 纯度: 99.88% Pirtobrutinib (LOXO-305) 是一种高选择性和非共价的下一代 BTK 抑制剂,可抑制多种 BTK C481 替代突变。Pirtobrutinib 导致小鼠异种移植模型中 BTK 依赖性淋巴瘤肿瘤的消退。Pirtobrutinib 对 BTK 的选择性也是 370 种其他激酶的 300 倍以上,并且在 ...